The OneStart Americas 2016 programme began back in Oct 2015, with launch events in Boston, Houston and San Francisco. Within a two-month window, a record breaking 380+ applications had been submitted for thorough review and judging by SR One, Oxbridge Biotech Roundtable and the OneStart partners. Not only was the breadth of ideas vast but they also looked to tackle head on some of the most pressing medical challenges of the 21st century. From cancer and diabetes to neurodegeneration.
Congratulations to the 10-finalist teams.
OneStart Americas 2016 – Finalists
Astraeus Technologies – Boston, United States.
We are creating an inexpensive, portable, accurate breath analysis device that will transform lung cancer screening.
Dynamic Boundaries Inc. – Ithaca, United States.
Our mission is to provide an effective treatment for osteoarthritis, one of the most prevalent and debilitating diseases.
Empire Biotechnologies – San Francisco, United States.
Developing the first orally delivered platform therapeutic for the many debilitating diseases of malabsorption.
InBrace – Huntingdon Beach, United States.
Behind-the-teeth, shape memory orthodontic solution w/ effectiveness of standard braces and comfort/ease of Invisalign.
Lelantus Medical – Palo Alto, United States.
Imagine you have a suspicious lesion in your lung, but no one can diagnose it. We have the solution.
Ovodex – Houston, United States.
Ovodex, accelerating cancer research and discovery, one egg at a time.
PathoVax – Baltimore, United States.
RGVax is a universal HPV vaccine that prevents all HPV disease with a cost-effective and established platform.
Sagacere Therapeutics – Toronto, Canada.
A promising treatment for primary progressive multiple sclerosis with neuroprotective and regenerative properties.
Suono Bio – Cambridge, United States.
Suono Bio is developing first-in-class devices for the ultra-rapid delivery of therapeutics to the GI tract.
Wickit Medical – Stanford, United States.
Wickit is an effective, low-cost solution to VAP, a lethal, hospital-acquired infection costing US healthcare $25B/year.